A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

By Ajani Jaffer   Jiang Yixing   Faust Josephine   Chang Baochong   Ho Linus   Yao James   Rousey Steven   Dakhil Shaker   Cherny Richard   Craig Catherine   Bleyer Archie  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 353-357

Springer Publishing Company

Access to resources Recommend Favorite

Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel

By Ajani Jaffer A  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1627-1631

Informa Healthcare

Access to resources Recommend Favorite

The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with gastroesophageal junction adenocarcinoma in Japan

By Koike T.   Ohara S.   Inomata Y.   Abe Y.   Iijima K.   Shimosegawa T.  

Inflammopharmacology, Vol. 15, Iss. 2, 2007-04 ,pp. : 61-64

Springer Publishing Company

Access to resources Recommend Favorite

Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions

By Richards Donald A   Boehm Kristi A   Anthony Stephen P  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-07 ,pp. : 1059-1068

Informa Healthcare

Access to resources Recommend Favorite

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study

By Martin-Richard M.   Gallego R.   Pericay C.   Foncillas J.   Queralt B.   Casado E.   Barriuso J.   Iranzo V.   Juez I.   Visa L.   Saigi E.   Barnadas A.   Garcia-Albeniz X.   Maurel J.  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1573-1579

Springer Publishing Company

Access to resources Recommend Favorite